Thymalfasin for the treatment of chronic hepatitis C infection

Research output: Chapter in Book/Report/Conference proceedingConference contribution

5 Scopus citations


The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-α2a and peginterferon-α2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-α2a plus thymalfasin or peginterferon-α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
PublisherBlackwell Publishing Inc.
Number of pages11
ISBN (Print)1573317012, 9781573317016
StatePublished - Sep 2007
Externally publishedYes

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

All Science Journal Classification (ASJC) codes

  • General Neuroscience
  • General Biochemistry, Genetics and Molecular Biology
  • History and Philosophy of Science


  • HCV
  • HCV nonresponders
  • Thymalfasin
  • Thymosin alpha 1
  • Zadaxin


Dive into the research topics of 'Thymalfasin for the treatment of chronic hepatitis C infection'. Together they form a unique fingerprint.

Cite this